Claudio Fiocchi, MD, Lerner Research Institute Department of Inflammation and Immunity, has been honored by the American Gastrological Association's Section on Immunology, Microbiology & Inflammatory Bowel Diseases (IMIBD) with its Research Mentor Award.
The award will be presented as part of the IMIBD abstract plenary session during "Digestive Disease Week" June 2-5, 2018 in Washington, DC. He joins a select group of 13 national honorees from the AGA Sections this year.
The prestigious award recognizes AGA members who have made lifelong efforts dedicated to mentoring trainees in gastroenterology. As Dr. Fiocchi also holds a joint appointment in Cleveland Clinic's Digestive Disease and Surgery Institute, his lab-which investigates immune events related to Crohn's disease and ulcerative colitis-offers trainees basic and clinical research perspectives.
Bioinformatics tools are now used to query and integrate the many complex factors in gastrointestinal disorders-including genomic, epigenomic, transriptomic, proteomic, metabolomic and microbiome information-to build a comprehensive molecular map of inflammatory bowel diseases (IBD). He coined the term "IBD Interactome" to describe the underlying disease network.
Among his many publications are novel results co-authored with colleagues and trainees in such journals as Nature Reviews: Gastroenterology and Hepatology, New England Journal of Medicine, Gut, and, of course, Gastroenterology. Dr. Fiocchi serves in editorial capacities for such journals as the Journal of Crohn's and Colitis and Inflammatory Bowel Diseases.
Staff
Lab Profile
Dr. Huang developed an innovative patient-derived model of the chronic inflammatory bowel disease that mirrors the disease’s complexity better than others currently available and identified the protein CXCL8 as an actionable drug target.
A new class of gut-restricted, oral therapies that target the enzyme glutamate carboxypeptidase II shows promise in treating inflammatory bowel disease (IBD).
Dr. Ahern will investigate the interplay between the gut microbiome and host immune response to understand how novel probiotic strategies may help modulate inflammation and one day be used to treat inflammatory bowel disease.
The future of health starts with your support. Donations supply researchers with the tools, space and staff they need to think big.
Give to Cleveland Clinic